IV Ketamine Shows Superior Results Over Nasal Esketamine for Treatment Resistant Depression
A new study reveals that intravenous ketamine delivers faster and more effective relief for patients with treatment resistant depression compared to its nasal counterpart, esketamine. The research examined 153 patients with severe depression who had failed multiple treatment attempts.
New:Â Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
| Key Finding | IV Ketamine | Nasal Esketamine |
|---|---|---|
| Depression reduction by 8th treatment | 49.22% | 39.55% |
| Time to significant improvement | After 1st treatment | After 2nd treatment |
| Study participants | 111 patients | 42 patients |
| Treatment delivery | Intravenous infusion | Intranasal spray |
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
Most clinics spend 4-6 weeks navigating Spravato REMS certification — chasing paperwork, decoding FDA requirements, and wondering if they missed a step. Our AI-powered REMS Certification Assistant cuts that to one sitting. Get a personalized checklist of exactly what you need, and walk into the REMS portal ready to submit.
Get the REMS Certification Assistant →Faster Response Times Transform Patient Outcomes
The study tracked patients through eight treatment sessions over four to five weeks. Researchers measured depression severity using standardized questionnaires before each session. IV ketamine patients showed significant improvement after just one treatment. Nasal esketamine users needed two sessions to reach similar milestones.
Both treatments target the brain’s glutamate system differently than traditional antidepressants. While conventional medications can take weeks to show effects, these ketamine based therapies work within hours or days. The speed difference between delivery methods surprised even experienced researchers.
RELATED: Ketamine For Depression: A Starting Guide
Treatment Resistant Depression Finds New Hope
The patients in this study represented some of the most challenging depression cases. Each participant had failed at least two adequate antidepressant trials before entering the ketamine program. Their baseline depression scores averaged 16 or higher on a 24 point scale, indicating severe symptoms.
Treatment resistant depression affects millions of Americans who cycle through multiple medications without relief. These patients often face hospitalization, disability, and increased suicide risk. The emergence of rapid acting treatments offers unprecedented hope for this vulnerable population.
Clinical Implications Shape Future Treatment Decisions
The research suggests IV ketamine provides superior efficacy over nasal esketamine in real world clinical settings. However, practical considerations complicate treatment choices. IV ketamine requires specialized clinics and longer appointment times. Nasal esketamine offers convenience with home administration after initial supervised sessions.
Insurance coverage varies significantly between treatments. Many insurers cover FDA approved nasal esketamine but reject IV ketamine claims. Patients often face difficult decisions balancing clinical effectiveness against financial accessibility.
The study represents one of the largest direct comparisons between these breakthrough treatments. As more data emerges, treatment guidelines will likely evolve to reflect these findings. For now, patients and providers must weigh efficacy gains against practical constraints when choosing between these revolutionary depression therapies.
